Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
12916
Phase 2 other active
Quick answer
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) for "Patients with interstitial lung disease associated pulmonary hypertension" is a Phase 2 program (other) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- "Patients with interstitial lung disease associated pulmonary hypertension"
- Phase
- Phase 2
- Modality
- other
- Status
- active